Induced pluripotent stem cells to model and treat neurogenetic disorders.
Remarkable advances in cellular reprogramming have made it possible to generate pluripotent stem cells from somatic cells, such as fibroblasts obtained from human skin biopsies. As a result, human diseases can now be investigated in relevant cell populations derived from induced pluripotent stem cells (iPSCs) of patients. The rapid growth of iPSC technology has turned these cells into multipurpose basic and clinical research tools. In this paper, we highlight the roles of iPSC technology that are helping us to understand and potentially treat neurological diseases. Recent studies using iPSCs to model various neurogenetic disorders are summarized, and we discuss the therapeutic implications of iPSCs, including drug screening and cell therapy for neurogenetic disorders. Although iPSCs have been used in animal models with promising results to treat neurogenetic disorders, there are still many issues associated with reprogramming that must be addressed before iPSC technology can be fully exploited with translation to the clinic.
Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON, Canada. hansen.wang@utoronto.ca
Hansen
H
Wang
Laurie C
LC
Doering
D000818:Animals; D002658:Developmental Disabilities / Q000235:genetics / Q000628:therapy; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009422:Nervous System Diseases / Q000235:genetics* / Q000628:therapy*; D039904:Pluripotent Stem Cells; D033581:Stem Cell Transplantation / Q000379:methods*